Moreover, in in vitro chemotherapy trials treatment of ADAM10 KO PDX cells from AML-661 and AML-356 with clinically relevant concentrations of Cytarabine, Doxorubicine and Daunorubicine, resulted in significant, dose-dependent reduction of ADAM10 KO cells compared to CTRL cells (Fig. S19). The gene discussed is ADAM10; the disease is acute myeloid leukemia.